DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction [ITI]Therapy, Gene Therapy), And Segment Forecasts to 2024" report to their offering.
The global hemophilia market is expected to reach USD 15.2 billion by 2024, according to this new report. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.
The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.
As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2013,including Nigeria, Togo, Mali, Zambia, Mauritania, and others.
Competitive pricing strategy is a vital factor promoting market players' growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.
Hemophilia B is expected to grow at a rapid rate of over 6.0% during the forecast period. Higher emphasis on pipeline products with an extended half-life and increasing incidence of hemophilia B affected patients are expected to be the prominent growth factors.
- Novo Nordisk
- Chugai Pharmaceutical Co.
- Bayer Healthcare
- Pfizer, Inc.
- Shire Plc.
- CSL Behring
1. Methodology And Scope
2. Executive Summary
3. Hemophilia Industry Outlook
4. Hemophilia Type Outlook
5. Hemophilia Treatment Outlook
6. Hemophilia Therapy Outlook
7. Hemophilia Regional Outlook
8. Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/qnwp9d/hemophilia_market